"液体肿瘤学"与"液体活检"Liquid Oncology vs Liquid Biopsy Liquid Oncology cfDNA Low concentration: average 17 ng/ml plasma in advanced-stage cancers Low proportion: tumor DNA can range between 0.01...
"液体肿瘤学"与"液体活检"Liquid Oncology vs Liquid Biopsy Liquid Oncology cfDNA Low concentration: average 17 ng/ml plasma in advanced-stage cancers Low proportion: tumor DNA can range between 0.01％ and 93％ CTC: ?, range 0～several thousands
HeadlinectDNA的由来液体活检临床需求数字化PCR(ddPCR)的临床应用总结临床个体化用药理念血浆游离DNA(ctDNA)的发现1948 First described cell-free nucleic acid in human blood 1994 Mutatad RAS gene fragrnent in cancer patients&...
HeadlinectDNA的由来液体活检临床需求数字化PCR(ddPCR)的临床应用总结临床个体化用药理念血浆游离DNA(ctDNA)的发现1948 First described cell-free nucleic acid in human blood 1994 Mutatad RAS gene fragrnent in cancer patients' blood 1996 Microsatellite alterations on cfDNA in cancer patients
Classification of lung cancer NSCLC (80％ ～ 85％)SCLC (15％～20％)Proposed Lung Cancer Biomarkers Research efforts to uncover biomarkars of earty-stage lung cancer have been *** biomarkers in a variety of body fluids...
Classification of lung cancer NSCLC (80％ ～ 85％)SCLC (15％～20％)Proposed Lung Cancer Biomarkers Research efforts to uncover biomarkars of earty-stage lung cancer have been *** biomarkers in a variety of body fluids have been proposed.
肿瘤传统诊断方式存在的问题Limitations of traditional clinical oncology paradigm Invasive Not always available Partial and temporal information Increase the risk of dissemination肿瘤常见诊疗手段存在的问题常规诊断手段...
肿瘤传统诊断方式存在的问题Limitations of traditional clinical oncology paradigm Invasive Not always available Partial and temporal information Increase the risk of dissemination肿瘤常见诊疗手段存在的问题常规诊断手段局限性影像学检查肿瘤信息获取滞后对身体的辐射性伤害血清标志物特异性不足组织病理有创操作无法作为实时监测手段
暂无评论